ABSTRACT: Background: Motor impairment in Parkinson’s disease (PD) reflects changes in the basal ganglia-thalamocortical circuit converging on the primary motor cortex (M1) and supplementary motor area (SMA). Previous studies assessed M1 excitability in PD using transcranial magnetic stimulation (TMS)-evoked electromyographic activity. TMS-evoked electroencephalographic activity may unveil broader motor cortical network changes in PD.

Objective: The aim was to assess motor cortical network excitability in PD.

Methods: We compared TMS-evoked cortical potentials (TEPs) from M1 and the pre-SMA between 20 PD patients tested off and on medication and 19 healthy controls (HCs) and investigated possible correlations with bradykinesia.

Results: Off PD patients compared to HCs had smaller P30 responses from the M1s contralateral (M1+) and ipsilateral (M1−) to the most bradykinetic side and increased pre-SMA N40. Dopaminergic therapy normalized the amplitude of M1+ and M1− P30 as well as pre-SMA N40. We found a positive correlation between M1+ P30 amplitude and bradykinesia in off PD patients.

Conclusions: Changes in M1 P30 and pre-SMA N40 in PD suggest that M1 excitability is reduced on both sides, whereas pre-SMA excitability is increased. The effect of dopaminergic therapy and the clinical correlation suggest that these cortical changes may reflect abnormal basal ganglia-thalamocortical activity. TMS electroencephalography provides novel insight into motor cortical network changes related to the pathophysiology of PD. © 2022 International Parkinson and Movement Disorder Society

Key Words: Parkinson’s disease; motor cortex; supplementary motor area; bradykinesia; transcranial magnetic stimulation-electroencephalography
MEPs, TEPs assess the activation of a larger range of neurons in the stimulated cortex and reflect both local cortical excitability and cortical and subcortical connectivity. When TMS is delivered over M1, TEPs within 60 ms after stimulation have been consistently linked to local cortical excitability and latency in milliseconds. Although P30, N45, and P60 components are likely generated in the sensorimotor area, propagation of TMS-evoked activity along the cortico-subcortical loops back-projecting to the cortex also contributes to these components. Therefore, TEPs may reveal changes in motor cortical activation in PD that cannot be identified when using MEPs as the outcome measure.

In the present study, we investigated whether TEPs could be used to identify changes in motor cortical network excitability in PD. To do so, we compared TEPs from M1 and the pre-SMA between PD patients and healthy controls (HCs). To test the effect of dopaminergic treatment on M1 and pre-SMA excitability and to determine whether cortical excitability changes are related to motor impairment, we investigated PD patients off (OFF) and on (ON) therapy and examined possible correlations between TEPs and clinical scores of motor impairment.

Patients and Methods

We consecutively enrolled 20 PD patients (12 men, aged 63.5 ± 10.8 years) and 19 age- and gender-matched HCs (10 men, aged 62.5 ± 9.2 years) from the outpatient unit at the Department of Human Neurosciences, Sapienza University of Rome, Italy (Table 1). HCs were enrolled from among nonconsanguineous relatives of patients. The study protocol was approved by the institutional review board and conducted in accordance with the latest revision of the Declaration of Helsinki. All patients provided written informed consent before participating in the study.

Clinical assessment included calculation of the levodopa equivalent daily dose, the Hoehn and Yahr (H&Y) scale, the Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Part III, and the Montreal Cognitive Assessment (MoCA). For eligibility, all participants had to be right-handed as assessed by the Edinburgh Handedness Inventory. Inclusion criteria for patients also included PD diagnosis confirmed by a movement disorder expert neurologist based on international criteria and the presence of bradykinesia with a minimum score of 2 on MDS-UPDRS items 3.4 to 3.6 related to the most affected upper limb, defined as the one showing the highest summed scores. Exclusion criteria included diagnosis of a neurological or psychiatric condition other than PD, advanced PD defined as H&Y stage IV or V, and cognitive decline (MoCA score <26) due to possible difficulties in compliance and medication withdrawal.

A Magstim SuperRapid stimulator (Magstim Company, Whitland, United Kingdom) connected to a 70-mm figure-of-eight coil was used to deliver TMS in the real stimulation condition. Sham stimulation was delivered by a 70-mm figure-of-eight sham coil (Magstim Company), which produces an auditory percept similar to real TMS without cortical activation. Neuronavigation (SofTaxic, EMS, Bologna, Italy) was used to adapt coil positioning for all stimulation sites. Using the neuronavigation system, we sampled 23 points from the scalp of each participant and adapted the reconstructed brain to Montreal Neurological Institute (MNI) space using nonlinear fitting. In all participants, the M1s of both sides were stimulated over the hotspot evoking the largest MEP in the contralateral first dorsal interosseous (FDI) muscle with posterior-anterior current direction. Resting motor threshold (RMT) was defined separately for each M1 as the minimum intensity required to elicit MEPs of ±50 μV peak-to-peak amplitude in at least 5 of 10 consecutive trials. For pre-SMA stimulation, the coil was placed with the handle pointing backward, parallel to the interhemispheric fissure and centered over the MNI coordinates x = 0, y = 10, z = 68. Coordinates for pre-SMA targeting were provided by previous studies but shifted to the midline (ie, x = 0) to produce focal activation of medial Brodmann area 6 (Figure S1A).

Electromyography (EMG) activity from the FDI was recorded through pairs of Ag/AgCl surface electrodes arranged in a belly-tendon montage. EMG signal was bandpass filtered (10–1000 Hz), amplified (×1000) (D360, Digitimer, Welwyn Garden City, United Kingdom), digitized at 5 kHz (CED1401, Cambridge Electronic Design, Cambridge, United Kingdom), and stored on a computer. EEG was recorded using a TMS-compatible amplifier (NeurOne, Bittium, Oulu, Finland) from 32 passive electrodes mounted on an elastic cap (BrainCap, EASYCAP, Worthersee, Germany) according to the international 10–20 system: Fp1-Fp2-AFz-F7-F3-Fz-F4-F8-FC5-FC1-FCz-FC2-FC6-T7-C3-Cz-C4-T8-TP9-CP5-CP1-CP2-CP6-TP10-P7-P3-P4-P8-O1-O2-Iz. EEG signal was bandpass filtered (DC-2.5 kHz) and digitized at 10 kHz. All electrodes were grounded to Fpz and online referenced to POz. Impedance for each channel was kept below 5 kΩ. Participants wore ear defenders (signal-to-noise ratio = 30) on top of earphones continuously playing a noise designed to mask
the TMS click. In addition, a 0.5-cm foam layer was placed under the coil to minimize bone conduction of the TMS click and scalp sensation caused by coil vibration.

Participants were comfortably seated on a chair designed for TMS (EMS), with their forearms resting on armrests. They were instructed to stay relaxed and look at a black cross displayed on a PC screen at a distance of 70 cm. FDI EMG activity was continuously monitored online, and participants were instructed to keep their hands relaxed. TMS trials showing EMG activity above 0.05 mV in the first second before each pulse were excluded online (always less than 5% of trials). Single TMS pulses were delivered during EEG and EMG recording using an intensity equal to 110% RMT during three blocks of real and three blocks of sham TMS over M1 left, M1 right, and the pre-SMA. Sham stimulation was performed on 15 patients and 13 HCs. Intensities were defined by asking each participant to report the maximal stimulation output value that best matched the perception of loudness of the TMS click produced by real stimulation on the same site and were on average 5%–10% higher than real stimulation values. However, participants were not informed about the presence of sham stimulation. The order of the blocks was randomized for each participant. One hundred TMS pulses were delivered in each block, with an interpulse interval of 1.65 s, a stimulation frequency that does not affect longitudinally recorded TEPs. We tested PD patients ON and OFF in two separate sessions performed 2–4 weeks apart and in a counterbalanced order across patients.

### TABLE 1 Patient demographics and clinical information

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (y)</th>
<th>Disease duration (y)</th>
<th>H&amp;Y</th>
<th>LEDD</th>
<th>MDS-UPDRS-III OFF</th>
<th>MDS-UPDRS-III ON</th>
<th>Most bradykinetic arm</th>
<th>Most affected upper limb bradykinetic OFF*</th>
<th>Most affected upper limb bradykinetic ON*</th>
<th>MoCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>78</td>
<td>3</td>
<td>2</td>
<td>300</td>
<td>27</td>
<td>14</td>
<td>R</td>
<td>5</td>
<td>2</td>
<td>30</td>
</tr>
<tr>
<td>2</td>
<td>71</td>
<td>5</td>
<td>2</td>
<td>400</td>
<td>32</td>
<td>22</td>
<td>R</td>
<td>8</td>
<td>4</td>
<td>26</td>
</tr>
<tr>
<td>3</td>
<td>53</td>
<td>1.5</td>
<td>1</td>
<td>70</td>
<td>28</td>
<td>17</td>
<td>L</td>
<td>6</td>
<td>5</td>
<td>28</td>
</tr>
<tr>
<td>4</td>
<td>73</td>
<td>6</td>
<td>2</td>
<td>600</td>
<td>33</td>
<td>21</td>
<td>L</td>
<td>6</td>
<td>5</td>
<td>26</td>
</tr>
<tr>
<td>5</td>
<td>54</td>
<td>1</td>
<td>1</td>
<td>180</td>
<td>15</td>
<td>13</td>
<td>R</td>
<td>5</td>
<td>4</td>
<td>30</td>
</tr>
<tr>
<td>6</td>
<td>44</td>
<td>1.5</td>
<td>1</td>
<td>400</td>
<td>19</td>
<td>13</td>
<td>R</td>
<td>4</td>
<td>4</td>
<td>30</td>
</tr>
<tr>
<td>7</td>
<td>73</td>
<td>9</td>
<td>2</td>
<td>500</td>
<td>38</td>
<td>35</td>
<td>R</td>
<td>7</td>
<td>7</td>
<td>26</td>
</tr>
<tr>
<td>8</td>
<td>65</td>
<td>5</td>
<td>2</td>
<td>400</td>
<td>38</td>
<td>24</td>
<td>L</td>
<td>8</td>
<td>5</td>
<td>30</td>
</tr>
<tr>
<td>9</td>
<td>76</td>
<td>3</td>
<td>2.5</td>
<td>300</td>
<td>30</td>
<td>21</td>
<td>R</td>
<td>6</td>
<td>5</td>
<td>27</td>
</tr>
<tr>
<td>10</td>
<td>70</td>
<td>10</td>
<td>2.5</td>
<td>600</td>
<td>46</td>
<td>34</td>
<td>R</td>
<td>5</td>
<td>3</td>
<td>26</td>
</tr>
<tr>
<td>11</td>
<td>51</td>
<td>2</td>
<td>1</td>
<td>300</td>
<td>19</td>
<td>13</td>
<td>L</td>
<td>7</td>
<td>4</td>
<td>30</td>
</tr>
<tr>
<td>12</td>
<td>63</td>
<td>2</td>
<td>1</td>
<td>450</td>
<td>20</td>
<td>10</td>
<td>R</td>
<td>6</td>
<td>3</td>
<td>27</td>
</tr>
<tr>
<td>13</td>
<td>44</td>
<td>2</td>
<td>2</td>
<td>552</td>
<td>22</td>
<td>12</td>
<td>R</td>
<td>7</td>
<td>4</td>
<td>28</td>
</tr>
<tr>
<td>14</td>
<td>58</td>
<td>12</td>
<td>2</td>
<td>452</td>
<td>21</td>
<td>9</td>
<td>R</td>
<td>4</td>
<td>3</td>
<td>30</td>
</tr>
<tr>
<td>15</td>
<td>66</td>
<td>4</td>
<td>2</td>
<td>300</td>
<td>33</td>
<td>23</td>
<td>R</td>
<td>6</td>
<td>4</td>
<td>27</td>
</tr>
<tr>
<td>16</td>
<td>64</td>
<td>1.5</td>
<td>1</td>
<td>450</td>
<td>24</td>
<td>19</td>
<td>L</td>
<td>5</td>
<td>4</td>
<td>30</td>
</tr>
<tr>
<td>17</td>
<td>58</td>
<td>2</td>
<td>1.5</td>
<td>200</td>
<td>27</td>
<td>22</td>
<td>L</td>
<td>4</td>
<td>1</td>
<td>27</td>
</tr>
<tr>
<td>18</td>
<td>69</td>
<td>10</td>
<td>2</td>
<td>300</td>
<td>24</td>
<td>18</td>
<td>R</td>
<td>5</td>
<td>4</td>
<td>28</td>
</tr>
<tr>
<td>19</td>
<td>81</td>
<td>3</td>
<td>2</td>
<td>300</td>
<td>23</td>
<td>16</td>
<td>L</td>
<td>3</td>
<td>3</td>
<td>30</td>
</tr>
<tr>
<td>20</td>
<td>58</td>
<td>1</td>
<td>2</td>
<td>100</td>
<td>11</td>
<td>9</td>
<td>R</td>
<td>3</td>
<td>3</td>
<td>27</td>
</tr>
<tr>
<td>Average</td>
<td>63.5</td>
<td>4.4</td>
<td>1.8</td>
<td>384.2</td>
<td>26.5</td>
<td>18.3</td>
<td>R/L:13/7</td>
<td>5.5</td>
<td>3.9</td>
<td>28.2</td>
</tr>
</tbody>
</table>

**SD** | 10.8 | 3.4 | 0.4 | 144.0 | 8.5 | 7.3 | 1.5 | 1.3 | 1.7 |

Abbreviations: Hoehn & Yahr; LEDD, levodopa equivalent daily dose; MDS-UPDRS, Movement Disorder Society–sponsored Unified Parkinson’s Disease Rating Scale; R, right; L, left; MoCA, Montreal Cognitive Assessment score; SD, standard deviation.

*Sum of scores 3.4, 3.5, and 3.6 of the MDS-UPDRS for the upper limb showing the highest score.
For the OFF session, patients discontinued their anti-parkinsonian medications at least 24 hours before the examination. HCs participated in a single experimental session.

We measured mean background muscular activity and peak-to-peak MEP amplitude for each participant (see Supplementary Material). TMS-EEG signal preprocessing was performed using the EEGLAB52 and TMS-EEG Signal Analyser (TESA)53,54 open-source Matlab (v.2017b) toolboxes (see Supplementary Material). Cleaned TMS-EEG epochs from –1.2 second before to 1.2 second after TMS pulses were converted into reference-free current source density (CSD) estimates using the “CSD”55 open-source Fieldtrip56 toolbox. Final TEPs were obtained by averaging TMS-EEG epochs (average number 93 ± 3) in each block. In patients, we defined the most affected M1 (M1+) and the least affected M1 (M1–), respectively, as the one contralateral and ipsilateral to the most affected upper limb. To obtain a homogeneous representation of scalp potential across groups, EEG electrode positions were mirrored across the two hemispheres in patients whose M1+ was the right one. The same was performed to compare TEPs from M1 left and M1 right in HCs. We compared M1 left and M1 right of HCs, respectively, with M1+ and M1– of PD patients.

Statistical analysis was performed using SPSS (version 25.0.0, IBM, Armonk, NY, US). Between-group (PD, HC) differences regarding age and gender were investigated using Mann-Whitney U and χ² tests. Paired or unpaired t tests were used to investigate differences in RMT, baseline EMG, and MEP amplitude between HCs and OFF and ON patients and to clarify changes in MDS-UPDRS scores according to medication (ON vs. OFF) conditions.

For each stimulation site, we computed grand average TEPs from all electrodes by averaging the mean TEPs in HCs and OFF and ON patients. We also computed local TEPs by averaging signals from the three channels closest to the stimulation site in each group (M1 left/ M1+: C3-Cz-FC1; M1 right/M1–: C4-Cz-FC2; pre-SMA: FCz-Fz-Cz). For each stimulation site, TEP components were defined as positive (P, or sources according to CSD estimates) or negative (N, or sinks according to CSD estimates) when showing a reversed U shape or a U shape on local TEPs, respectively. Analysis was limited within 60 ms after stimulation because this latency range has been more consistently related to local cortical excitability21 and may also reflect cortico-subcortical dynamics.20,32-34,57,58

We measured the peak latency of each TEP component as the time point of the maximal baseline-to-peak...
FIG. 2. TEPs from stimulation of the M1 ipsilateral to the most bradykinetic upper limb. Above: grand average butterfly plots of CSD-transformed TEPs from all channels; green lines represent the signal close to the stimulation site (average across C4, FC2, Cz). Below: topo plots of the investigated times of interest; black cross shows approximate stimulation site; yellow represents positive CSD values (sources); blue represents negative values (sinks); squares highlight significant comparisons; asterisks highlight channels significantly different in cluster-based permutation analysis. CSD, current source density; TEP, TMS-evoked cortical potential. [Color figure can be viewed at wileyonlinelibrary.com]

FIG. 3. TEPs from pre-SMA stimulation. Above: grand average butterfly plots of CSD-transformed TEPs from all channels; green lines represent the signal close to the stimulation site (average across Cz, FCz, Fz). Below: topo plots of the investigated times of interest; black cross shows approximate stimulation site; yellow represents positive CSD values (sources); blue represents negative values (sinks); squares highlight significant comparisons; asterisks highlight channels significantly different in cluster-based permutation analysis. CSD, current source density; SMA, supplementary motor area; TEP, TMS-evoked cortical potential. [Color figure can be viewed at wileyonlinelibrary.com]
<table>
<thead>
<tr>
<th>Correlations</th>
<th>Pre-SMA N40 OFF</th>
<th>Con. brad. OFF</th>
<th>Ips. brad. OFF</th>
<th>Pre-SMA N40 ON</th>
<th>Con. brad. ON</th>
<th>Pre-SMA N40 HC</th>
<th>UPDRS-III OFF</th>
<th>UPDRS-III ON</th>
<th>Con. brad. OFF and ON</th>
</tr>
</thead>
<tbody>
<tr>
<td>M1+ P30 OFF</td>
<td>rs = −0.62 q = 0.01</td>
<td>rs = 0.59 q = 0.01</td>
<td>rs = 0.26 q = 0.35</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>rs = −0.03 q = 0.90</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>M1− P30 OFF</td>
<td>rs = 0.23 q = 0.93</td>
<td>rs = −0.11 q = 0.93</td>
<td>rs = 0.01 q = 0.97</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>rs = −0.92 q = 0.93</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>M1+ P30 ON</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>rs = −0.29 q = 0.32</td>
<td>rs = 0.11 q = 0.63</td>
<td>–</td>
<td>–</td>
<td>rs = −0.38 q = 0.30</td>
<td>–</td>
</tr>
<tr>
<td>M1+ P30 OFF and ON</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>rs = 0.10 P = 0.52</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>M1 left P30 HC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>rs = −0.49 P = 0.03</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Pre-SMA N40 OFF</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>rs = −0.06 P = 0.80</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Pre-SMA N40 ON</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>rs = −0.16 P = 0.51</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Upper limb bradykinesia, summed scores of MDS-UPDRS subitems 3, 4, 5, and 6; UPDRS-III, MDS-UPDRS; q-values, FDR (false discovery rate)-adjusted P-values; each filled column was considered a correlation in the FDR correction.

Abbreviations: SMA, supplementary motor area; con. brad., contralateral upper limb bradykinesia; Ips. brad., ipsilateral upper limb bradykinesia; MDS-UPDRS, Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale; M1+, contralateral to the most bradykinetic upper limb; M1−, contralateral to the less bradykinetic upper limb.
amplitude value on grand average TEPs across groups, and we defined the following time window of interest (TOI) for M1—P30 (28 ± 5 ms), N45 (46 ± 5 ms), and P60 (62 ± 5 ms)—and for the pre-SMA: P20 (19 ± 5 ms) and N40 (39 ± 5 ms) (Figure S1B). TEP components in each TOI were compared between groups (HCs vs. PD) and conditions (OFF vs. ON, and left vs. right in HCs) separately for real and sham TMS using cluster-based permutation testing as implemented in Fieldtrip (clusters were significant with a P-value < 0.05 false discovery rate [FDR] corrected for multiple cluster occurrence)59 (see Supplementary Material). To test whether the interpulse interval we used influenced TEPs, we measured whether TEP amplitude changed during M1+ block (see Supplementary Material). We assessed Spearman’s correlations on average TEP amplitude across the channels in the clusters significantly affected by parkinsonian state between different stimulation sites to test possible common mechanisms underlying TEP abnormalities in PD. We assessed the same correlations in HCs to test whether the results were specific for PD. We also computed correlations between these TEPs and bradykinesia scores from both upper limbs to test the side specificity of our results. We corrected for multiple correlations by computing FDR with the one-stage method60 (see Supplementary Material). All values are expressed as mean ± standard deviation.

Results

Mean age of PD patients and HCs did not differ statistically (U = 176.5, P = 0.71). There was no significant difference in the proportion of men/women between patients and HCs (χ²(1) = 0.22, P = 0.64). Patients showed significantly lower MDS-UPDRS scores in the ON versus OFF condition (t(19) = 9.94, P < 0.001) (Table 1). RMT, background EMG activity, and MEP amplitude were similar between groups and conditions (see Table S1).

Average TEPs showed that the first components (P30 for M1 stimulation and P20 for pre-SMA stimulation) had maximal activity close to the stimulation site (Figs. 1–3). After M1 stimulation of both sides, P30 topography showed a centro-frontal source predominant over the stimulated hemisphere. In N45 and P60 TOIs, the dominant source of activity progressively moved posteriorly over centro-parietal sites, and contralateral frontal and parietal sinks were noted (Figs. 1 and 2).

After pre-SMA stimulation, there was a medial c-frontal source in the P20 TOI and a medial central sink in the N40 TOI (Fig. 3).

Considering the M1 of both sides, there was significantly smaller activity in the P30 centro-frontal source in OFF patients than in HCs (M1+ cluster: C3-FCz-FC1-FC2; M1– cluster: FCz-Fz-FC1-FC2) (Fig. 1). We found no differences in TEPs evoked by left and right M1 stimulation in HCs. After pre-SMA stimulation, OFF PD patients showed significantly larger activity in the N40 sink over centro-frontal areas (Fz-AFz) than HCs (Fig. 3). N45 and P60 from each M1 and pre-SMA P20 were comparable between groups.

We found significant negative correlations between M1+ P30 amplitude and pre-SMA N40 amplitude in OFF PD patients and HCs, whereas no significant correlation was found in ON patients (Figure S2) (Table 2).

Sham stimulation of M1 on both sides and the pre-SMA induced no detectable TEPs, and sham blocks were similar between groups and medication conditions (Figures S3–S5).

After M1 stimulation on both sides, patients had significantly higher amplitude in the P30 centro-frontal source (M1+: C3-Cz-FC1; M1–: Fz-FC2) in the ON versus OFF condition. We found no differences in M1 P30, N45, or P60 on either side between ON patients and HCs. Dopaminergic treatment did not affect M1 N45 or P60 of either side (Figs. 1 and 2). The pre-SMA N40 sink over the medial frontal areas (Fz, AFz, FC1, and FC2) was significantly smaller in the ON versus OFF condition, and we found no differences in pre-SMA N40 between patients ON and HCs. Dopaminergic treatment did not affect pre-SMA P20 amplitude (Fig. 3). All significant clusters survived FDR correction (Table S2). Cluster-based analysis in both HCs and OFF patients showed no significant differences in TEPs between the first, the second, and the last third of TMS epochs.

In OFF patients, M1+ P30 amplitude showed a strong positive correlation with bradykinesia scores in the contralateral more affected upper limb but no correlation with the ipsilateral/less-affected upper limb. No significant correlations were found in the ON condition, when whole OFF and ON values were considered together, or for M1– P30. Finally, no significant correlations were found between MDS-UPDRS-III scores and M1+ and M1– P30 amplitude or pre-SMA N40 amplitude (Figure S2) (Table 2).

Discussion

The present study revealed several TEP changes in PD. In OFF PD patients, the P30 component of TEPs evoked by M1 stimulation of both hemispheres was smaller than in HCs. In contrast, N40 TEPs from pre-SMA stimulation were larger in OFF patients compared to HCs. In OFF patients, there was a significant correlation between the amplitudes of M1 P30 and pre-SMA N40. Finally, sham stimulation did not elicit TEPs from
either site. Dopaminergic treatment increased the size of P30 evoked by stimulation of M1 in both hemispheres, whereas the size of pre-SMA N40 decreased. M1 P30 and pre-SMA N40 sizes did not differ between ON PD patients and HCs. Finally, in OFF PD patients there was a significant correlation between the size of M1+P30 and contralateral bradykinesia clinical scores, whereas no correlations were found between M1 and pre-SMA TEPs and MDS-UPDRS-III score.

We excluded several confounding factors. Previous work had shown that interpulse intervals around 1 second can produce long-term changes in MEPs.61 However, we found that TEP amplitude obtained by averaging the first third of TMS epochs did not significantly differ from TEP amplitude observed in the second and last third of trials for HCs or OFF patients. This analysis suggests that possible short-term effects did not confound our results. Our results were likely not confounded by EEG responses caused by auditory input because sham stimulation evoked no significant activity.48,49 This result also shows that the concurrent use of a layer of foam under the coil, ear defenders, and noise masking effectively suppresses auditory responses even for suprathreshold TMS intensities.48,49 The possibility that our TEPs reflect nonspecific sensory responses is also reduced by the observation that TEPs showed topographic specificity.18,21,22,48 Finally, although TEPs evoked by stimulation intensities above motor threshold may be contaminated by sensory reaferents associated with muscle contraction, our results mainly concern latencies preceding this possible confounding factor,62,63 and because MEP amplitudes were similar between groups and conditions, sensory reaferents could not explain the TEP differences we found.

Alterations in TEP size from the M1 and pre-SMA suggest that PD is associated with abnormalities in cortical motor network excitability. TEPs are generated by a summation of excitatory and inhibitory postsynaptic potentials generated by the activity of cortical pyramidal neurons and interneurons and reflect cortical excitability.16-22 Animal intracortical recordings from layer 5 showed a significant increase in the firing rate of pyramidal neurons in the P30 time range33 and reduced pyramidal neuron activity in animal models of PD.4,5,64 Therefore, the decreased P30 amplitude after stimulation of M1 on both sides likely reflects reduced excitability of M1 pyramidal neurons in OFF PD patients.3-5 Besides local cortical excitability, TEPs reflect the connectivity of the stimulated area with other cortical and subcortical areas, and therefore, TEP abnormalities may reflect motor network changes in PD.22-25 Cortico-subcortical loops involving thalamocortical projections may contribute to TEPs in the 10- to 50-ms range,20,32-34 and the P30 distribution we observed is consistent with it being the cortical source of a radial dipole with a subcortical sink. We speculate that one circuit that contributes to P30 is an excitatory cortico-subcortical network through the basal ganglia and thalamus and back to the cortex.57,58 Reduced excitability in this network in PD would result in reduced thalamocortical excitation and reduced P30.1,2 However, degeneration of thalamic dopamine innervation has recently been described in PD animal models, and therefore, P30 changes in PD may reflect thalamic changes unrelated to basal ganglia abnormalities.65 Reduced M1 P30 is consistent with the reduced motor-related M1 activation reported by neuroimaging studies66 and provides evidence of PD-related neural dysfunction that is not confounded by differences in motor task performance because TEPs were recorded at rest.

The observed reduction in M1 P30 amplitude in PD patients confirms the results of a recent non-sham-controlled TMS-EEG study that was performed in a smaller group of advanced PD patients implanted with deep brain stimulation.67 Our finding of increased pre-SMA N40 amplitude suggests pre-SMA hyperexcitability in PD, which is consistent with the hyperactivation reported by neuroimaging studies.66 N40 distribution was compatible with a radial dipole, with centro-frontal negativity generated by corticofugal outputs. Therefore, increased pre-SMA N40 amplitude may reflect changes along cortico-subcortical circuits in PD.56,68

Our finding of increased pre-SMA TEPs in PD contrasts with that recently reported in a similar study.46 However, while we centered the coil over the midline, Casarotto and colleagues stimulated a more lateral area, eliciting TEPs that may receive larger contributions from the dorsal premotor cortex (PMd).

We found that dopaminergic therapy normalized P30 elicited by M1 stimulation of both hemispheres as well as pre-SMA N40. Also, dopaminergic treatment modulated the correlation between M1 P30 and pre-SMA N40 observed in OFF PD patients. This result confirms that TEPs provide a useful indicator of dopaminergic therapy effect on motor cortical excitability in PD. Our finding that dopaminergic therapy normalized M1 P30 and pre-SMA N40 amplitudes suggests that abnormalities in these components in PD reflect motor cortical changes due to abnormal basal ganglia-thalamocortical activity.1,2

Correlation analyses demonstrated that OFF PD patients who were more bradykinetic had larger M1+P30, whereas no correlations were found in ON PD patients, even when whole ON and OFF state values were considered together. The lack of correlation in the ON condition suggested that reduced P30 size in PD is not a direct marker of bradykinesia. Because P30 reduction inversely correlated with contralateral bradykinesia in OFF PD patients, decreased P30 may reflect M1 compensatory mechanisms to maintain motor output in
the OFF state. Alternatively, the lack of correlation in the ON condition could be due to a smaller dispersion of bradykinesia scores in the ON versus OFF condition that may have limited the sensitivity of the correlation analysis in ON PD patients. However, this possibility is unlikely because Table 1 shows similar standard deviation of bradykinesia scores between OFF and ON conditions.

We acknowledge some limitations. Although we found that the short interpulse interval we used likely did not affect TEP amplitude, our MEP analysis could have been confounded by possible mechanisms related to the dependence of consecutive responses. Future studies using interpulse intervals >5 seconds are necessary for a better comparison between TMS-EEG and TMS-EMG responses. Although our sham stimulation produced a tactile vibratory sensation, somatosensory co-stimulation was not completely controlled for in sham blocks. However, somatosensory co-stimulation does not contribute significantly to the early TEPs considered in the present study. Because we did not use individual MRI neuronavigation, variability in pre-SMA and SMA-proper locations may have confounded TEP results due to distinctive functional changes occurring in the pre-SMA and SMA-proper in PD. However, because we centered our coil over pre-SMA coordinates that did not overlap with the SMA-proper, and because our estimated electric field maximal values (Figure S1) were within the boundaries of the pre-SMA maximal probability area, we believe that our methods resulted in high spatial selectivity for pre-SMA activation with limited confounding due to SMA coactivation. Also, the increase in pre-SMA TEPs is in line with the pre-SMA hyperactivation previously reported, supporting the conclusion that our results likely reflect pre-SMA excitability. Although bilateral pre-SMA activation in our study could have limited our sensitivity to identify asymmetrical pre-SMA involvement in PD, a recent meta-analysis suggested bilateral pre-SMA hyperactivation in PD. In addition, TEPs elicited by more lateral coil placement would have been confounded by the mixed activation of different premotor areas. We acknowledge that since the reported effect sizes were calculated posteriori, they are likely overestimated, and therefore, studies with larger samples and hypothesis-driven designs are warranted to confirm our results and reach more definitive conclusions. Studies on patients with other movement disorders are also necessary to test the specificity of our results in PD.

In conclusion, our TMS-EEG study demonstrated motor cortical network excitability changes in PD and their relationship with nigrostriatal degeneration, findings that have important pathophysiological and clinical implications. We demonstrated that TEPs can be used to identify motor cortical activation changes in PD without the need for the motor-related tasks used in other neuroimaging studies. In addition, our study showed that TEPs reveal changes in the excitability of neuronal populations that differ from those found using MEPs and that may partially reflect changes in circuits involving subcortical structures sensitive to dopaminergic status. Further studies are needed to clarify the relevance of our results to PD pathophysiology and their clinical correlates.

Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.

References


Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.
Author Roles


G.L.: 1A, 1B, 1C, 2B, 3A
M.I.B.: 1B, 1C, 3A
A.G.: 1A, 1C, 1B
A.F.: 1B, 2B, 3B
L.R.: 1A, 1B, 3B
A.L.: 1B, 1C, 3B
G.P.: 1C, 3B
D.P.: 1B, 3B
A.C.: 1A, 3B
K.P.B.: 1A, 3B
J.C.R.: 1A, 3B
A.B.: 1A, 1B, 1C, 3B

Full financial disclosures for the previous 12 months

G.L.: none.
M.I.B.: none.
A.F.: none.
L.R.: none.
G.P.: none.
D.P.: none.
A.C.: none.
K.P.B. has received grant support from Horizon 2020 EU grant 634821 and honoraria/financial support to speak at/attend meetings from GSK, Boehringer-Ingelheim, Ipsen, Merz, Sun Pharma, Allergan, Teva, Lundbeck, and Orion Pharmaceutical. K.P.B. receives royalties from the Oxford University Press and a stipend for MDCP editorship.
A.B.: none.